Globus Medical (GMED)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$78.29+0.22%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · GMED
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -29.5% |
| Our one-year growth estimate | diamond | 5.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 35.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
GMED — officer change
Dated 2026-06-04
The filing describes an amendment to the equity incentive plan, not a management change.
Why it matters: A slowdown in US Spine growth could indicate loss of competitive edge in a key segment.
Worry ifUS Spine growth reported below 5% year over year.
Less concerning ifUS Spine growth reported above 5% year over year.
Why it matters: A slowdown in net income growth may show problems with costs or sales. This is important for checking overall performance.
Worry ifNet income growth reported below 50% year over year.
Less concerning ifNet income growth reported at or above 50% year over year.
Why it matters: Board changes can change company strategy and how investors feel about it.
Watch forA new board member joins. They have the right experience or vision.
Also watch forMore board members leave without new ones joining or clear plans.
Why it matters: Lowering EPS guidance may mean weaker profit expectations. This could hurt investor confidence.
Worry ifNon-GAAP EPS guidance for 2026 revised down below $4.95.
Less concerning ifNon-GAAP EPS guidance for 2026 maintained or raised above $4.95.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$144 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $320 loss on $10,000 · 3.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,210 loss on $10,000 · 22.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If sector revenue growth drops, it may impact GMED's growth potential. This is important for understanding market conditions.
Worry ifSector revenue growth reported below its median.
Less concerning ifSector revenue growth remains above its median.
Why it matters: Changes in the board can affect company plans and trust from investors.
Watch forA new board member with industry experience has been announced.
Also watch forThere are no new board members or negative comments about board changes.
Why it matters: This shows good cost control and helps with profit goals.
Supportive ifQ3 adjusted gross margin expands by 200 basis points or more.
Worry ifQ3 adjusted gross margin contracts or expands less than 100 basis points.
Why it matters: Falling below this EPS range may show trouble in making money. This could hurt investor trust in future growth.
Worry ifNon-GAAP diluted EPS was below $4.70 for 2026.
Less concerning ifNon-GAAP diluted EPS reported at or above $4.70 for 2026.
Why it matters: Meeting this EPS target shows earnings are growing and operations are running well.
Supportive ifNon-GAAP EPS for Q3 reaches or exceeds $1.34.
Worry ifNon-GAAP EPS for Q3 falls below $1.20.
Why it matters: Successful integration of Nevro is key for keeping revenue growth. Delays or problems could hurt overall performance.
Watch forGood news on the integration process has led to more sales from Nevro.
Also watch forBad news on integration problems has led to fewer sales from Nevro.
Why it matters: A slowdown in revenue growth shows problems in keeping market share and momentum.
Worry ifQ3 revenue growth reported below 5% year over year.
Less concerning ifQ3 revenue growth exceeds 5% year over year.
Why it matters: Falling margins may mean higher costs or problems. This can hurt profits.
Worry ifMargin expansion was reported below 200 basis points from the prior year.
Less concerning ifMargin expansion reported at or above 200 basis points compared to the prior year.
Why it matters: Slow growth in operating income may mean costs are going up or things are not working well.
Worry ifOperating income growth is less than 10% compared to last year.
Less concerning ifOperating income growth exceeds 10% year over year.